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Introduction: Hypoxia is known to play a central role in many oncologic processes providing the common link among tumor aggressiveness, poor 
outcome and resistance to different therapies (1,2). Consequently, a variety of methods have been proposed to measure tumour oxygenation in vivo 
and in vitro (3). In particular, several nitroimidazole derivatives (SR-4554, EF5) have been used in combination with either optical microscopy 
methods (EF5, Pimonidazole) or nuclear medicine approaches (SR-4554, 18F-MISO) (4). The procedure is based on the selective reduction and 
trapping of these derivatives in hypoxic regions of the tumor in vivo (5). These approaches require the use of either tissue biopsies for histological 
analysis or PET scanners and cyclotron associated synthetic facilities. It would become then useful to develop an in vivo NMR protocol, compatible 
with currently available scanners, to observe in situ the metabolism of nitroimidazoles in tumors under different oxygenation conditions. The present 
work reports, for the first time to our knowledge, the in vivo 1H NMR detection of some commercially available nitromidazole derivatives under 
normoxic and hypoxic conditions. 
 
Subjects and Methods: Nude mice were implanted with C6 glioblastoma cells in the flanks. Tumors were allowed to grow up to 1 cm diameter. 
Animals were then anesthetized using Isoflurane (1.5%) and either medical air or 100% oxygen, receiving a single intratumoral  injection (multisite) 
of misonidazole 1 M (300 mg/kg (6)) + TSP 2 M. TSP was added to the injection to monitor the wash out of a non reducible compound. The hypoxia 
sensitive probe misonidazole was expected to be both, 
selectively reduced  in hypoxic zones, as well as cleared 
from the tumor (as TSP) by circulation, disappearing 
then at a faster rate than the non reducible reference The 
time course of the probes inside the tumor after the 
injection was followed using single voxel spectroscopy 
(125 μL) using a PRESS sequence (7T Bruker 
PharmaScan, number of scan =128, TR= 3000 ms, TE = 
20 ms, acquisition time = 7 min). During the 
experiments, animals breathed air or pure oxygen. The 
area of TSP and Misonidazole resonances were 
normalized to the mobile lipid methylene resonances (1,3 
ppm), which did not change appreciably during the time 
course of these experiments. Normalized decays of TSP 
and Misonidazole resonances with time, were fitted non 
lineasrly to a single exponential decay (y=(y0 - 
plateau)*exp(-k*x) + plateau, where: y0 and pleateau 
represent the y values at zero and infinite time, and k is 
the rate constant of disappearance (min-1), respectively 
 
Results: Figure 1a shows the 1H PRESS spectrum of the tumor obtained before and after the injection of the Misonidazole + TSP mixture. The 
resonances of the H4 and H5 protons of the imidazole ring are easily observed in the aromatic region (between 7 and 8 ppm, green square). 
Simultaneously, the TSP resonance (at 0 ppm) becomes clearly detectable (purple square). These resonances disappear from the tumor with time. 
The process appears to follow first order kinetics, as shown in the representative study depicted in Figure 1b. The decay is characterized by a rate 
constant k, which is different for the misonizadole or TSP 
compounds. 
 
The degree of tumor hypoxia can be modified if the animal 
breathes either normal medical air (21% oxygen) or 100% 
oxygen. Comparing the rate constants fitted when the 
animals were breathing air or oxygen, clearly significant 
differences were found with misonidazole, with slower 
reduction rates in those animals breathing oxygen as 
expected (Figure 2a). However, the TSP probe disappeared 
at very similar rates in the two different oxygenation states, 
as expected for a hypoxia insensitive molecule (Figure 2b). 
 
Conclusions: We have monitored by in vivo 1H-MRS the 
in vivo kinetics of disappearance of the pO2 sensitive 
misonidazole probe from a tumor in vivo. We demonstrate 
that the rate of disappearance of the misonidazole is 
dependent of the oxygen tension in the tumor, while the 
time course of the non reducible TSP reference is not. We 
propose that the methodology implemented here in may be used to evaluate the oxygen tension of tumors in vivo by monitoring the rate of reduction 
of the oxygen-sensitive nitroimidazolil probes. This approach offers in addition the possibility to combine the pO2 measurement with other MRI 
(DCE, ADC, Perfusion… ) or MRSI (pHe) imaging methodologies. 
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